New selective inhibitors of MMP-13 for inflammatory diseases: A patent evaluation (W02012151158)

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 5, 2013, Pages 669-675

  Li, Nian Guang ^a   Tang, Yu Ping ^a   Duan, Jin Ao ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Inhibitor; Isoxazoline; MMP 13; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

COLLAGENASE 3; COLLAGENASE INHIBITOR;

ARTICLE; BIOLOGICAL ACTIVITY; CHEMICAL REACTION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; INFLAMMATORY DISEASE; JUVENILE RHEUMATOID ARTHRITIS; NONHUMAN; OSTEOARTHRITIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; DRUG DESIGN; HUMANS; INFLAMMATION; ISOXAZOLES; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE INHIBITORS; PATENTS AS TOPIC;

EID: 84876518309     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.779254     Document Type: Article

References (25)

1. Brooks PM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumatol 2002;14:573-7 (Pubitemid 34953798)
2. Wollheim FA. Current pharmacological treatment of osteoarthritis. Drugs 1996;52:27-38 (Pubitemid 26366542)
3. McAlindon T. Glusoamine for osteoarthritis: dawn of a new era? Lancet 2001;357:247-8 (Pubitemid 32120851)
4. Chard J, Dieppe P. Glucosamine for osteoarthritis: magic, hype, or confusion? BMJ 2001;322:1439-40
5. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6 (Pubitemid 32120855)
6. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4
7. Murphy G, Nagase H. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat Clin Pract Rheumatol 2008;4:128-35 (Pubitemid 351338627)
8. Li NG, Shi ZH, Tang YP, Duan JA. Selective matrix metalloproteinase inhibitors for cancer. Curr Med Chem 2009;16:3805-27
9. Johnson AR, Pavlovsky AG, Ortwine DF, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007;282:27781-91 (Pubitemid 47529503)
10. Billinghurst RC, Dahlberg L, Ionescu M, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45 (Pubitemid 27163804)
11. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92 (Pubitemid 34270240)
12. Levitt NC, Eskens FALM, O'Byrne KJ, et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 2001;7:1912-22 (Pubitemid 32994825)
13. Li NG, Shi ZH, Tang YP, et al. New hope for the treatment of osteoarthritis through selective inhibition of MMP-13. Curr Med Chem 2011;18:977-1001
14. Li W, Hua Y, Li J, et al. 3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding. Bioorg Med Chem Lett 2009;19:4546-50
15. Kolodziej SA, Hockerman SL, DeCrescenzo GA, et al. MMP-13 selective isonipecotamide alpha-sulfone hydroxamates. Bioorg Med Chem Lett 2010;20:3561-4
16. Gao DA, Xiong Z, Heim-Riether A, et al. SAR studies of non-zinc-chelating MMP-13 inhibitors: Improving selectivity and metabolic stability. Bioorg Med Chem Lett 2010;20:5039-43
17. Savi CD, Morley AD, Nash I, et al. Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2. Bioorg Med Chem Lett 2012;22:271-7
18. Blagg JA, Noe MC, Wolf-Gouveia LA, et al. Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. Bioorg Med Chem Lett 2005;15:1807-10 (Pubitemid 40380737)
19. McGeehan GM, Becherer JD, Bast RC, et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 1994;370:558-61 (Pubitemid 24264921)
20. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science 1998;282:1281-4 (Pubitemid 28524483)
21. Gallea-Robache S, Morand V, Millet S, et al. A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. Cytokine 1997;9:340-6 (Pubitemid 27248243)
22. Hooper NM, Kariran EH, Turner AJ. Membrane protein secretases. Biochem J 1997;321:265-79 (Pubitemid 27056469)
23. Montana J, Baxter A. The design of selective non-substrate-based matrix metalloproteinase inhibitors. Curr Opin Drug Discov Devel 2000;3:353-61 (Pubitemid 30470035)
24. Rubino MT, Agamennone M, Campestre C, et al. Synthesis, SAR, and biological evaluation of alpha-sulfonylphosphonic acids as selective matrix metalloproteinase inhibitors. ChemMedChem 2009;4:352-62
25. Agrawal A, Romero-Perez D, Jacobsen JA, et al. Zinc-binding groups modulate selective inhibition of MMPs. ChemMedChem 2008;3:812-20